Trazodone for Major Depressive Disorder and Insomnia

Initiation and Dosing for Major Depressive Disorder

For major depressive disorder, trazodone should be initiated at 150 mg daily (preferably as a single dose at bedtime) and titrated to 150–300 mg/day for full antidepressant efficacy. 1, 2, 3

Starting Dose and Titration Schedule

Begin with 150 mg once daily at bedtime after a meal or light snack to minimize side effects and optimize absorption. 1, 4
Titrate over 2 weeks to the individual optimal dose based on efficacy and tolerability, with a target range of 150–300 mg/day for antidepressant effect. 5
Maximum studied dose is 375 mg/day, though most patients respond adequately to 150–300 mg/day. 5
Single nighttime dosing is preferred over divided doses because it reduces daytime drowsiness while improving sleep, with equal antidepressant efficacy. 4

Rationale for Dosing Strategy

The 2022 VA/DoD guideline now includes trazodone as a recommended option for MDD (upgraded from the 2016 guideline), reflecting emerging evidence of efficacy. 6
Trazodone demonstrates comparable efficacy to SSRIs and tricyclic antidepressants for reducing depressive symptoms, with particular advantages for patients with comorbid insomnia, anxiety, or psychomotor agitation. 2, 3, 7
Extended-release formulations maintain therapeutic blood levels for 24 hours while avoiding concentration peaks associated with side effects, potentially improving adherence. 2, 5

Use in Insomnia: Strong Evidence Against

Trazodone should NOT be used as a primary treatment for insomnia disorder in adults. 8

Guideline Position on Insomnia

The American Academy of Sleep Medicine (2017) explicitly recommends against using trazodone for sleep-onset or sleep-maintenance insomnia (weak recommendation against use). 8
This negative recommendation is based on insufficient evidence of efficacy for insomnia as a primary diagnosis and a significant adverse-effect profile that outweighs potential benefits. 8, 9
Low doses of trazodone (≤50 mg) commonly prescribed off-label for insomnia lack proven benefit and carry risks including orthostatic hypotension, falls, and cardiac effects. 8, 9

When Trazodone May Be Appropriate for Sleep

Trazodone is appropriate for insomnia occurring as a symptom of major depressive disorder, where it addresses both depression and sleep disturbance at antidepressant doses (150–300 mg/day). 2, 3, 10
In MDD patients, trazodone significantly improves sleep quality (Pittsburgh Sleep Quality Index SMD = -0.827, p = 0.001) while simultaneously reducing depression severity. 10

Absolute Contraindications

Do not prescribe trazodone in the following circumstances: 1

Concurrent use of monoamine oxidase inhibitors (MAOIs) or within 2 weeks of MAOI discontinuation (risk of serotonin syndrome). 1
Pregnancy (no established safety data). 9, 1
Severe hepatic insufficiency. 9
Compromised respiratory function or untreated obstructive sleep apnea. 9
History of complex sleep-related behaviors (e.g., sleep-driving). 9

Critical Safety Warnings and Monitoring

Black Box Warning: Suicidality

Antidepressants, including trazodone, increase the risk of suicidal thoughts and behaviors in children, adolescents, and young adults (≤24 years) during the first few months of treatment. 1
Monitor closely for new or worsening depression, suicidal ideation, agitation, panic attacks, insomnia, irritability, hostility, or impulsivity, especially during dose changes. 1
Schedule frequent follow-up visits in the first 4–6 weeks and instruct patients/caregivers to report any sudden mood or behavior changes immediately. 1

Cardiovascular Risks

Orthostatic hypotension is a common adverse effect, particularly in older adults and patients with pre-existing cardiovascular disease; measure orthostatic vital signs before initiation and during titration. 2
QT interval prolongation and cardiac arrhythmias have been reported; obtain baseline ECG in patients with cardiac risk factors. 2
Priapism is a rare but serious adverse effect requiring immediate medical attention; counsel male patients about this risk. 2

Serotonin Syndrome

Risk is elevated when trazodone is combined with other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, fentanyl, lithium, St. John's Wort, or MAOIs). 1
Symptoms include agitation, confusion, tachycardia, hypertension, hyperthermia, hyperreflexia, diaphoresis, tremor, and diarrhea; instruct patients to seek emergency care if these occur. 1

Bleeding Risk

Concomitant use with NSAIDs, aspirin, antiplatelet agents, or anticoagulants increases bleeding risk; counsel patients and consider gastroprotection if indicated. 1

Discontinuation Syndrome

Abrupt cessation can cause withdrawal symptoms including nausea, headache, irritability, and rebound insomnia; taper gradually over several weeks when discontinuing. 1

Common Adverse Effects

Most frequent: somnolence, headache, dizziness, and dry mouth (xerostomia). 2
Sedation and somnolence are dose-dependent; single nighttime dosing mitigates daytime drowsiness. 4
Blurred vision (OR = 17.50 vs. placebo) and sedation (OR = 6.53) are significantly more common with trazodone than placebo. 10
Low risk of weight gain, sexual dysfunction, and anticholinergic effects compared to SSRIs and tricyclics, which may improve long-term adherence. 2, 3

Administration Instructions

Take shortly after a meal or light snack to reduce gastrointestinal side effects and optimize absorption. 1
Swallow tablets whole or break in half along the score line; do not chew or crush. 1
Avoid alcohol and other CNS depressants during treatment to prevent additive sedation and respiratory depression. 9, 1
Ensure ≥7–8 hours of planned sleep time when taking the dose to minimize next-day residual effects. 9

Special Populations

Older Adults

Use lower starting doses and titrate cautiously due to increased risk of orthostatic hypotension, falls, and cognitive impairment. 2
Monitor orthostatic vital signs closely during initiation and dose adjustments. 2

Hepatic or Renal Impairment

Dose reduction is required in patients with liver or kidney disease; consult prescribing information for specific adjustments. 1

Pregnancy and Lactation

Trazodone is not recommended during pregnancy due to lack of safety data; if used, enroll patients in the National Pregnancy Registry for Antidepressants (1-844-405-6185). 1
Trazodone passes into breast milk; discuss risks and benefits of breastfeeding with the patient. 1

Drug Interactions Requiring Dose Adjustment or Avoidance

MAOIs: Absolute contraindication (2-week washout required). 1
CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): May increase trazodone levels; consider dose reduction. 1
CYP3A4 inducers (e.g., carbamazepine, phenytoin): May decrease trazodone efficacy; consider dose increase. 1
Warfarin: Monitor INR closely due to potential for altered anticoagulation. 1

Efficacy Timeline and Response Assessment

Onset of antidepressant effect typically occurs within 1–2 weeks, with continued improvement over 4–8 weeks. 5, 7
Reassess efficacy and tolerability at weeks 2,4,8, and 12 using standardized rating scales (e.g., HAM-D, MADRS). 5, 7
Response rate (≥50% symptom reduction) is comparable to SSRIs, with remission rates of 54.5% reported in naturalistic studies. 7, 11
If no response after 4–6 weeks at adequate dose (≥150 mg/day), consider alternative or augmentation strategies. 6

Advantages Over SSRIs in Specific Clinical Contexts

Superior for patients with MDD and comorbid insomnia, as trazodone improves both depression and sleep without the insomnia exacerbation seen with SSRIs. 2, 3, 10
Lower risk of sexual dysfunction and emotional blunting compared to SSRIs, which may be critical for adherence. 2, 7
Effective for anxiety symptoms and psychomotor agitation in depressed patients. 3, 7
Reduces alcohol craving in patients with comorbid MDD and alcohol use disorder, making it a valuable option in dual-diagnosis populations. 11

How should trazodone be initiated and titrated for insomnia or major depressive disorder, including contraindications and dosing recommendations?

Have a follow-up question?